Contributor Page
Norton Rose Fulbright Canada LLP
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 2164000
Fax: +1 416 2163930
Suite 3800
Royal Bank Plaza, South Tower
200 Bay Street, P.O. Box 84
Ontario M5J 2Z4
Contributor Most Read
Contributor Most Read
By Nader Hasan
The CSA has issued Staff Notice 51-357 Staff Review of Reporting Issuers in the Cannabis Industry, which identifies deficiencies in the disclosure practices of issuers involved in the rapidly growing cannabis industry.
By Ryan Berger
Like many organizations in Canada, yours is probably not fully prepared for the mandatory breach reporting requirements coming into force under the federal Personal Information Protection and Electronic Documents Act (PIPEDA) November 1, 2018.
By Christopher Guerreiro, Kristin Wall, Judith Robinson
As we reported, Canada has joined a new trilateral trade deal called the United States-Mexico-Canada Agreement (USMCA).
By Jillian Hyslop, Kristin Wall, Sara Zborovski
Health Canada recently published a notice outlining its phase III pre-market transparency initiatives for prescription drugs.
By Rika Sawatsky
Recreational cannabis will become legal in Canada effective October 17, 2018.
By Sara Zborovski
On October 9, U.S. Customs and Border Protection (the CBP) released a Statement on Canada's Legalization of Marijuana and Crossing the Border.
By Amanda Ferriss
The authors argue that confidentiality agreements and fiduciary duties can be used to help mitigate the foregoing risks.
By Sean Williamson
Thomson Reuters recently released a report on global mergers and acquisitions in the first nine months of 2018
By Ted Brook
The Ontario Superior Court of Justice has released what appears to be the final chapter in the Ontario Securities Commission's (OSC) prosecution of Daniel Emerson Tiffin and Tiffin Financial Corporation.
By Norton Rose Fulbright Canada LLP
L'accord États-Unis-Mexique-Canada auquel le Canada a adhéré le 30 septembre dernier réserve une belle surprise pour votre portfolio de brevets.
By Norton Rose Fulbright Canada LLP
Les médicaments biologiques sont complexes car ils sont issus du métabolisme d'un organisme vivant.
By Ahad Ahmed
On September 18, Deloitte released a new report which outlines a roadmap for the competitive business climate in Canada. Included in the report is a warning that "Canada may have a zombie problem."
By Danny Urquhart
On September 27 the Competition Bureau and the Public Prosecution Service of Canada launched revised immunity and leniency programs in relation to investigating and prosecuting criminal offences under the Competition Act.
By Caroline Larouche
As there is almost never direct, ‘smoking gun' type evidence of insider trading, securities regulators often rely on circumstantial evidence in enforcement proceedings, from which they invite the specialized securities tribunals to draw inferences.
By Erika Anschuetz
On September 6, 2018, the Canadian Securities Administrators (CSA) issued a notice and request for comment on Proposed National Instrument 52-112 Non-GAAP and Other Financial Measures Disclosure, ...
Contributor's Topics